Metabolism active phase

Investigation of the differences in crystal packing between (431) and (426) from comparison of their respective X-ray structures, revealed that (431) was more tightly packed than (442), reflected in their respective melting points of 235 and 170 °C. It was postulated that the absence of in vivo activity for (431) may be explained by the resultant reduction in water solubility and dissolution rate compared with (426). The comparatively high calculated polar surface area of (431) (122.5A ) compared with (426) (89.3 A ) was also proposed as a factor influencing the marked difference in bioavailability between the two related compounds. Compound (426) (SLV-319) is currently being developed with Bristol-Myers Squibb for the potential treatment of obesity and other metabolic disorders. Phase I trials for obesity were started in April 2004. Earlier Phase I clinical trials for the treatment of schizophrenia and psychosis, which commenced in April 2002, appear to have been abandoned. 

Biological activity can be used in two ways for the bioremediation of metal-contaminated soils to immobilize the contaminants in situ or to remove them permanently from the soil matrix, depending on the properties of the reduced elements. Chromium and uranium are typical candidates for in situ immobilization processes. The bioreduction of Cr(VI) and Ur(VI) transforms highly soluble ions such as CrO and UO + to insoluble solid compounds, such as Cr(OH)3 and U02. The selenate anions SeO are also reduced to insoluble elemental selenium Se°. Bioprecipitation of heavy metals, such as Pb, Cd, and Zn, in the form of sulfides, is another in situ immobilization option that exploits the metabolic activity of sulfate-reducing bacteria without altering the valence state of metals. The removal of contaminants from the soil matrix is the most appropriate remediation strategy when bioreduction results in species that are more soluble compared to the initial oxidized element. This is the case for As(V) and Pu(IV), which are transformed to the more soluble As(III) and Pu(III) forms. This treatment option presupposes an installation for the efficient recovery and treatment of the aqueous phase containing the solubilized contaminants. 

Phase-shifting by melatonin is attributed to its action at MT2 receptors present in the SCN (Liu et al. 1997). The chronobiological effect of melatonin is due to its direct influence on the electrical and metabolic activity of the SCN, a finding that has been confirmed both in vivo and in vitro. The application of melatonin directly to the SCN significantly increases the amplitude of the melatonin peak, thereby suggesting that in addition to its phase-shifting effect melatonin directly acts on the amplitude of the oscillations (Pevet et al. 2002). However, this amplitude modulation seems to be unrelated to clock gene expression in the SCN (Poirel et al. 2003). 

As predicted, MCH l orexin mice displayed an intermediate body weight phenotype, indicating independent and opposing neuromodulatory actions of MCH and orexin on metabolism. Surprisingly, however, rather than expressing an attenuated narcoleptic phenotype, MCHr orexin l mice exhibited more severe behavioral state instability during the active phase. When compared with orexin mice, the double null mice had about twice as many cataplectic episodes (Fig. 15.7A), they were less able to maintain wakefulness, and... 

If metabolic activation is not required, treatment is best conducted over the whole of the final 24 h of culture, or if metabolic activation is required a pulse exposure may be employed to treat cultures at the first S phase at around 24-30 h, or at 48 h for an asynchronous population. 

Mammalian cells in culture are exposed to the test substance. Established cell lines are treated both with and without metabolic activation. Cells are incubated for an appropriate length of time, then rinsed, fixed, and dried. Slides are developed, stained, and exposed silver grains are counted. The endpoint of UDS is measured by determining the uptake of labeled nucleosides in cells that are not undergoing scheduled (S-phase) DNA synthesis. The most widely used technique is the determination of the uptake of H-TdR by autoradiography. Primary cultures (e.g., rat hepatocytes), human lymphocytes, or established cell lines (e.g., human diploid fibroblasts) may be used in the assay. Multiple concentrations of the test substance over a range adequate to define the response, should be used. 

Occurrence of complex dissimilar actions is thought to be rare at low exposure (ADI) levels but it should always be considered whether a plausible hypothesis exists for effect interactions of two or more compounds. Interactions can occur both in the toxicodynamic phase (e.g., endocrine disrup-tors) and in the toxicokinetic phase (e.g., interference with transport, metabolism (activation, deactivation), distribution, and elimination of another compound). 

Phase III reactions occur primarily in plants presumably because excretion of Phase II conjugates is Insignificant in plants. Phase III reactions are mechanisms whereby plants can reduce the effective concentration of xenobiotlc compounds in the cytoplasm. Thus, conjugation reactions provide mechanisms for the elimination of xenobiotlc compounds from sites of continuing metabolic activity in all organisms ( ) ... 

First, the effects of aerobic and anaerobic culture conditions on toxaphene degradation were studied with washed P. putida cells grown on camphor and incubated with no readily usable carbon source. The radioactivities remaining in water after extraction with n-hexane were used as an indicator of metabolic activity. This was further extracted with ethyl acetate after acidification to divide this "total polar metabolites" fraction into aqueous buffer phase and ethyl acetate phase, i.e., the total polar metabolites reported refer to summation of the aqueous buffer and ethyl acetate soluble phases (Table 4). All radioactivities have been corrected by zero time controls and autoclaved 8 hr controls are included in each experiment. 

Bande JA et al (1999) Phase III interlaboratory study of FETAX, Part 3 FETAX validation using 12 compoimds with and without an exogenous metabolic activation system. J Appl Toxicol 19 447 72... 

---